{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:29:21Z","timestamp":1776288561363,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["201500400"],"award-info":[{"award-number":["201500400"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s10549-016-3801-4","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T11:27:17Z","timestamp":1461583637000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer"],"prefix":"10.1007","volume":"157","author":[{"given":"Yukiko","family":"Tabuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Kagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Tanei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinzaburo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"key":"3801_CR1","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.4049\/jimmunol.178.4.1975","volume":"178","author":"G Parmiani","year":"2007","unstructured":"Parmiani G, De Filippo A, Novellino L, Castelli C (2007) Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178:1975\u20131979","journal-title":"J Immunol"},{"key":"3801_CR2","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"O Finn","year":"2008","unstructured":"Finn O (2008) Cancer immunology. N Engl J Med 358:2704\u20132715","journal-title":"N Engl J Med"},{"key":"3801_CR3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/pr700818f","volume":"7","author":"H Lu","year":"2008","unstructured":"Lu H, Goodell V, Disis ML (2008) Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:1388\u20131394","journal-title":"J Proteome Res"},{"key":"3801_CR4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdm007","volume":"18","author":"C Chapman","year":"2007","unstructured":"Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868\u2013873","journal-title":"Ann Oncol"},{"key":"3801_CR5","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","volume":"15","author":"F Graus","year":"1997","unstructured":"Graus F, Dalmou J, Rene R et al (1997) Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15:2866\u20132872","journal-title":"J Clin Oncol"},{"key":"3801_CR6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0304-4157(95)00014-3","volume":"1241","author":"S Patton","year":"1995","unstructured":"Patton S, Gendler SJ, Spicer AP (1995) The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241:407\u2013423","journal-title":"Biochim Biophys Acta"},{"key":"3801_CR7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1020360121451","volume":"7","author":"J Taylor-Papadimitriou","year":"2002","unstructured":"Taylor-Papadimitriou J, Burchell JM, Plunkett T et al (2002) MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7:209\u2013221","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"3801_CR8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2000.18.3.574","volume":"18","author":"S Mensdorff-Pouilly von","year":"2000","unstructured":"von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574\u2013583","journal-title":"J Clin Oncol"},{"key":"3801_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Ann Rev Immunol 29:235\u2013271","journal-title":"Ann Rev Immunol"},{"key":"3801_CR10","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","volume":"184","author":"DJ DiLillo","year":"2010","unstructured":"DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4\u00a0+\u00a0and CD8\u00a0+\u00a0T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184:4006\u20134016","journal-title":"J Immunol"},{"key":"3801_CR11","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1158\/1078-0432.CCR-11-0207","volume":"17","author":"Q Li","year":"2011","unstructured":"Li Q, Lao X, Pan Q et al (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17:4987\u20134995","journal-title":"Clin Cancer Res"},{"key":"3801_CR12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature14424","volume":"521","author":"Y Carmi","year":"2015","unstructured":"Carmi Y, Spitzer MH, Linde IL et al (2015) Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 521:99\u2013104","journal-title":"Nature"},{"key":"3801_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med 357:39\u201351","journal-title":"N Engl J Med"},{"key":"3801_CR14","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.1997.15.11.3363","volume":"15","author":"ML Disis","year":"1997","unstructured":"Disis ML, Pupa SM, Gralow JR et al (1997) High-titer HER-2\/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363\u20133367","journal-title":"J Clin Oncol"},{"key":"3801_CR15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1515\/CCLM.2011.135","volume":"49","author":"JJL Lauterlein","year":"2011","unstructured":"Lauterlein JJL, Petersen ER, Olsen DA et al (2011) Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer. Clin Chem Lab Med 49:877\u2013883","journal-title":"Clin Chem Lab Med"},{"key":"3801_CR16","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2003.04.576","volume":"21","author":"A Goldhirsch","year":"2003","unstructured":"Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357\u20133365","journal-title":"J Clin Oncol"},{"key":"3801_CR17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","volume":"16","author":"A Goldhirsch","year":"2005","unstructured":"Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569\u20131583","journal-title":"Ann Oncol"},{"key":"3801_CR18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","volume":"18","author":"A Goldhirsch","year":"2007","unstructured":"Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133\u20131144","journal-title":"Ann Oncol"},{"key":"3801_CR19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319\u20131329","journal-title":"Ann Oncol"},{"key":"3801_CR20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1349-7006.2009.01151.x","volume":"100","author":"K Morimoto","year":"2009","unstructured":"Morimoto K, Kim SJ, Tanei T et al (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100:1062\u20131068","journal-title":"Cancer Sci"},{"key":"3801_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jim.2005.02.002","volume":"299","author":"V Goodell","year":"2005","unstructured":"Goodell V, Disis ML (2005) Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 299:129\u2013138","journal-title":"J Immunol Methods"},{"key":"3801_CR22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.650.65.2","volume":"65","author":"RB Montgomery","year":"2005","unstructured":"Montgomery RB, Makary E, Schiffman K et al (2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650\u2013656","journal-title":"Cancer Res"},{"key":"3801_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377\u2013384","journal-title":"Lancet"},{"key":"3801_CR24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","volume":"358","author":"S Paik","year":"2008","unstructured":"Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409\u20131411","journal-title":"N Engl J Med"},{"key":"3801_CR25","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1200\/JCO.2009.26.2154","volume":"28","author":"EA Perez","year":"2010","unstructured":"Perez EA, Reinholz MM, Hillman DW et al (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307\u20134315","journal-title":"J Clin Oncol"},{"key":"3801_CR26","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-12-3349","volume":"73","author":"S Ithimakin","year":"2013","unstructured":"Ithimakin S, Day KC, Malik F et al (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73:1635\u20131646","journal-title":"Cancer Res"},{"key":"3801_CR27","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/jnci\/djt321","volume":"105","author":"KL Pogue-Geile","year":"2013","unstructured":"Pogue-Geile KL, Kim C, Jeong JH et al (2013) Predicting degree of benefit from adjuvant trastuzumab in NSABP Trial B-31. J Natl Cancer Inst 105:1782\u20131788","journal-title":"J Natl Cancer Inst"},{"key":"3801_CR28","first-page":"159","volume":"6","author":"A Milani","year":"2014","unstructured":"Milani A, Sangiolo D, Aglietta M, Valabrega G (2014) Recent advances in the development of breast cancer vaccines. Breast Cancer 6:159\u2013168","journal-title":"Breast Cancer"},{"key":"3801_CR29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","volume":"25","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Clifton GT, Holmes JP et al (2014) Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 25:1735\u20131742","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3801-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3801-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T23:20:54Z","timestamp":1718493654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3801-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3801"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3801-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,25]]}}}